Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of “Hold” from Brokerages
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has received a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. […]
More Stories
Diamondback Energy (NASDAQ:FANG) Price Target Raised to $219.00
Diamondback Energy (NASDAQ:FANG – Get Free Report) had its target price lifted by equities researchers at Wells Fargo & Company...
D. Boral Capital Reiterates Buy Rating for TETRA Technologies (NYSE:TTI)
TETRA Technologies (NYSE:TTI – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital...
Jefferies Financial Group Raises Honeywell International (NASDAQ:HON) Price Target to $260.00
Honeywell International (NASDAQ:HON – Get Free Report) had its target price hoisted by equities research analysts at Jefferies Financial Group...
IQVIA Holdings Inc. (NYSE:IQV) Stock Position Decreased by B. Riley Wealth Advisors Inc.
B. Riley Wealth Advisors Inc. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 12.8%...
Brown & Brown, Inc. (NYSE:BRO) Stock Position Lowered by Retirement Systems of Alabama
Retirement Systems of Alabama lowered its position in shares of Brown & Brown, Inc. (NYSE:BRO – Free Report) by 1.2%...
UBS Group Initiates Coverage on Synovus Financial (NYSE:SNV)
Investment analysts at UBS Group started coverage on shares of Synovus Financial (NYSE:SNV – Get Free Report) in a report...